Metabolon Selected for Membership in NCI Research Group
News Dec 01, 2005
This is Metabolon’s second project with NCI but first project as a member of the EDRN will be a collaboration with the University of Michigan to discover disease biomarkers for prostate cancer.
"Membership in the EDRN is a great privilege," said Dr. John Ryals, president and CEO of Metabolon.
"Metabolon will be able to collaborate with other members to discover and develop biomarkers for the early diagnosis of cancers."
Metabolon will share its technology and metabolomics expertise with Dr. Arul Chinnaiyan of the University of Michigan on the prostate cancer project.
"Metabolon is at the forefront in the emerging area of metabolomics, and we are extremely excited about embarking on this collaboration," said Dr. Chinnaiyan.
"If metabolomic biomarkers can be identified for prostate cancer, Metabolon’s technology platform may have applications in other cancers as well."
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
Immune Cells Form Clots in Tumors Aiding Lung Cancer's SpreadNews
Researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.READ MORE